China · Delayed Price · Currency is CNY Newland Pharmaceutical Statistics
Total Valuation
SHE:301277 has a market cap or net worth of CNY 3.96 billion. The enterprise value is 3.34 billion.
| Market Cap | 3.96B |
| Enterprise Value | 3.34B |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | Apr 30, 2026 |
Share Statistics
SHE:301277 has 392.08 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Current Share Class | 392.08M |
| Shares Outstanding | 392.08M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 63.57% |
| Owned by Institutions (%) | 1.12% |
| Float | 99.62M |
Valuation Ratios
The trailing PE ratio is 38.18.
| PE Ratio | 38.18 |
| Forward PE | n/a |
| PS Ratio | 5.57 |
| PB Ratio | 2.58 |
| P/TBV Ratio | 2.67 |
| P/FCF Ratio | 96.31 |
| P/OCF Ratio | 43.67 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.05, with an EV/FCF ratio of 81.34.
| EV / Earnings | 32.17 |
| EV / Sales | 4.71 |
| EV / EBITDA | 19.05 |
| EV / EBIT | 29.52 |
| EV / FCF | 81.34 |
Financial Position
The company has a current ratio of 6.52, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.52 |
| Quick Ratio | 5.94 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.10 |
| Interest Coverage | 1,425.31 |
Financial Efficiency
Return on equity (ROE) is 6.72% and return on invested capital (ROIC) is 10.86%.
| Return on Equity (ROE) | 6.72% |
| Return on Assets (ROA) | 4.02% |
| Return on Invested Capital (ROIC) | 10.86% |
| Return on Capital Employed (ROCE) | 7.11% |
| Weighted Average Cost of Capital (WACC) | 5.25% |
| Revenue Per Employee | 724,308 |
| Profits Per Employee | 105,994 |
| Employee Count | 981 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 6.39 |
Taxes
In the past 12 months, SHE:301277 has paid 13.56 million in taxes.
| Income Tax | 13.56M |
| Effective Tax Rate | 11.71% |
Stock Price Statistics
The stock price has decreased by -26.22% in the last 52 weeks. The beta is 0.18, so SHE:301277's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -26.22% |
| 50-Day Moving Average | 10.34 |
| 200-Day Moving Average | 11.30 |
| Relative Strength Index (RSI) | 44.99 |
| Average Volume (20 Days) | 6,157,459 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301277 had revenue of CNY 710.55 million and earned 103.98 million in profits. Earnings per share was 0.26.
| Revenue | 710.55M |
| Gross Profit | 212.11M |
| Operating Income | 113.31M |
| Pretax Income | 115.77M |
| Net Income | 103.98M |
| EBITDA | 173.70M |
| EBIT | 113.31M |
| Earnings Per Share (EPS) | 0.26 |
Balance Sheet
The company has 618.62 million in cash and 4.22 million in debt, with a net cash position of 614.40 million or 1.57 per share.
| Cash & Cash Equivalents | 618.62M |
| Total Debt | 4.22M |
| Net Cash | 614.40M |
| Net Cash Per Share | 1.57 |
| Equity (Book Value) | 1.53B |
| Book Value Per Share | 3.91 |
| Working Capital | 885.55M |
Cash Flow
In the last 12 months, operating cash flow was 90.69 million and capital expenditures -49.57 million, giving a free cash flow of 41.12 million.
| Operating Cash Flow | 90.69M |
| Capital Expenditures | -49.57M |
| Depreciation & Amortization | 60.39M |
| Net Borrowing | -942,329 |
| Free Cash Flow | 41.12M |
| FCF Per Share | 0.10 |
Margins
Gross margin is 29.85%, with operating and profit margins of 15.95% and 14.63%.
| Gross Margin | 29.85% |
| Operating Margin | 15.95% |
| Pretax Margin | 16.29% |
| Profit Margin | 14.63% |
| EBITDA Margin | 24.45% |
| EBIT Margin | 15.95% |
| FCF Margin | 5.79% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 1.97%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 1.97% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 75.41% |
| Buyback Yield | -0.87% |
| Shareholder Yield | 1.10% |
| Earnings Yield | 2.63% |
| FCF Yield | 1.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 16, 2025. It was a forward split with a ratio of 1.4.
| Last Split Date | Apr 16, 2025 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |